Pei Lin

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

39h-index44.1kcitations101works22.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(22), Cancer Genomics and Diagnostics(19), Chronic Lymphocytic Leukemia Research(15), RNA Research and Splicing(10), Viral-associated cancers and disorders(10)

Publications73 total

Decoding Dental Stem Cell Aging: Mechanisms, Therapeutic Strategies, and Beyond
Advanced Science·2025Open Access
Mesenchymal stromal cell-mediated mitochondrial transfer unveils new frontiers in disease therapy
Stem Cell Research & Therapy·2025· 5 citedOpen Access
Genome-wide mapping of RNA-protein associations through sequencing
Nature Biotechnology·2025· 3 citedOpen Access
Mitochondrial Regulation of CD8⁺ T Cells: Mechanisms and Therapeutic Modulation
Advanced Science·2025· 9 citedOpen Access
Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment
Materials Today Bio·2025· 6 citedOpen Access
Transcriptional regulation by PHGDH drives amyloid pathology in Alzheimer’s disease
Cell·2025· 5 citedOpen Access
1218 B-Lymphoblastic Leukemia/Lymphoma Arising in Patients with Multiple Myeloma
Laboratory Investigation·2025Open Access
Nanovaccines empowering CD8<sup>+</sup> T cells: a precision strategy to enhance cancer immunotherapy
Theranostics·2025· 14 citedOpen Access
Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases
Modern Pathology·2025· 5 cited
Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments
Materials Today Bio·2024· 9 citedOpen Access
Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies
Theranostics·2024· 14 citedOpen Access
Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment
Cell Death and Disease·2024· 38 citedOpen Access
Optimizing CD8+ T cell-based immunotherapy via metabolic interventions: a comprehensive review of intrinsic and extrinsic modulators
Experimental Hematology and Oncology·2024· 11 citedOpen Access
Development and Validation of a Cholesterol-related Gene Signature for Prognostic Assessment in Head and Neck Squamous Cell Carcinoma
Current Medicinal Chemistry·2024
Tumor Microenvironment-Derived Exosomes: A Double-Edged Sword for Advanced T Cell-Based Immunotherapy
ACS Nano·2024· 26 cited
P-223 Clinicopathologic Features of 73 Patients with TP53 Mutated Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy
Cell Death and Disease·2024· 253 citedOpen Access
High-Resolution Characterization of Human Brain Cortex with High-Fidelity Spatial Transcriptomic Slides (HiFi-Slides)
2023Open Access
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies
Modern Pathology·2023· 7 citedOpen Access
Canalization of Phenotypes—When the Transcriptome is Constantly but Weakly Perturbed
Molecular Biology and Evolution·2023· 14 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

L. Jeffrey Medeiros(18), Michael S. Lawrence(8), Yuexin Liu(8), Rehan Akbani(8), Rupa S. Kanchi(8), Yunfan Lin(8), Xinyuan Zhao(8), Michael S. Noble(7), David I. Heiman(7), Gad Getz(7), Ilya Shmulevich(7), Thomas J. Giordano(7), Vésteinn Thórsson(7), Anil Korkut(7), Shaoying Li(7), C. Cameron Yin(7), Gordon Saksena(6), Rory Johnson(6), John A. Demchok(6), Ina Felau(6)